Gain Therapeutics Stock Performance
| GANX Stock | USD 1.74 0.01 0.58% |
Gain Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.08, which attests to a somewhat significant risk relative to the market. Gain Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Gain Therapeutics is expected to follow. Use Gain Therapeutics sortino ratio, as well as the relationship between the semi variance and rate of daily change , to analyze future returns on Gain Therapeutics.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Gain Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Gain Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Saudi Arabia expects to get access to Nvidias high performance chips within the next year | 09/13/2024 |
2 | Acquisition by Alder Matthias of 79200 shares of Gain Therapeutics subject to Rule 16b-3 | 09/17/2024 |
3 | Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinsons Disease Models Including Two Late-Breakers at Neuroscience 2024 | 09/19/2024 |
4 | Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinsons Disease and Movement Disorders Demonstrating Increase in GCase Activity... | 09/30/2024 |
5 | Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - StockTitan | 10/07/2024 |
6 | Gain Therapeutics Regains Nasdaq Compliance - Investing.com | 10/21/2024 |
7 | Acquisition by Hasler Hans Peter of 10500 shares of Gain Therapeutics at 4.5 subject to Rule 16b-3 | 10/24/2024 |
8 | Gain Therapeutics Parkinsons Drug Shows 53 percent Activity Boost in Phase 1 Trial GANX Stock News - StockTitan | 11/14/2024 |
9 | Gain Therapeutics shares hold Buy rating H.C. Wainwright optimistic on GT-02287 clinical data | 11/25/2024 |
| Begin Period Cash Flow | 7.3 M | |
| Free Cash Flow | -18.9 M |
Gain |
Gain Therapeutics Relative Risk vs. Return Landscape
If you would invest 107.00 in Gain Therapeutics on August 29, 2024 and sell it today you would earn a total of 66.00 from holding Gain Therapeutics or generate 61.68% return on investment over 90 days. Gain Therapeutics is currently generating 1.001% in daily expected returns and assumes 7.1787% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Gain, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Gain Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gain Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gain Therapeutics, and traders can use it to determine the average amount a Gain Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1394
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GANX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.18 actual daily | 63 63% of assets are less volatile |
Expected Return
| 1.0 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Gain Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gain Therapeutics by adding it to a well-diversified portfolio.
Gain Therapeutics Fundamentals Growth
Gain Stock prices reflect investors' perceptions of the future prospects and financial health of Gain Therapeutics, and Gain Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gain Stock performance.
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 34.61 M | ||||
| Shares Outstanding | 26.53 M | ||||
| Price To Book | 5.15 X | ||||
| Price To Sales | 925.92 X | ||||
| Revenue | 55.18 K | ||||
| Gross Profit | (7.66 M) | ||||
| EBITDA | (22.17 M) | ||||
| Net Income | (22.27 M) | ||||
| Cash And Equivalents | 24.25 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 7.58 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (18.87 M) | ||||
| Earnings Per Share | (1.07) X | ||||
| Market Capitalization | 45.89 M | ||||
| Total Asset | 18.61 M | ||||
| Retained Earnings | (60.78 M) | ||||
| Working Capital | 12.83 M | ||||
About Gain Therapeutics Performance
Evaluating Gain Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Gain Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Gain Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 197.37 | 175.44 | |
| Return On Tangible Assets | (1.21) | (1.27) | |
| Return On Capital Employed | (1.63) | (1.55) | |
| Return On Assets | (1.20) | (1.26) | |
| Return On Equity | (1.77) | (1.68) |
Things to note about Gain Therapeutics performance evaluation
Checking the ongoing alerts about Gain Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gain Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gain Therapeutics is way too risky over 90 days horizon | |
| Gain Therapeutics may become a speculative penny stock | |
| Gain Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 55.18 K. Net Loss for the year was (22.27 M) with loss before overhead, payroll, taxes, and interest of (7.66 M). | |
| Gain Therapeutics currently holds about 24.25 M in cash with (18.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Gain Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Gain Therapeutics shares hold Buy rating H.C. Wainwright optimistic on GT-02287 clinical data |
- Analyzing Gain Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gain Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Gain Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gain Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gain Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gain Therapeutics' stock. These opinions can provide insight into Gain Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.